Ragazzini R, Pérez-Palacios R, Baymaz IH, Diop S, Ancelin K, Zielinski D, Michaud A, Givelet M, Borsos M, Aflaki S et al (2019) EZHIP constrains polycomb repressive complex 2 activity in germ cells. Nat Commun 10:3858. https://doi.org/10.1038/s41467-019-11800-x

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jain SU, Do TJ, Lund PJ, Rashoff AQ, Diehl KL, Cieslik M, Bajic A, Juretic N, Deshmukh S, Venneti S et al (2019) PFA ependymoma-associated protein EZHIP inhibits PRC2 activity through a H3 K27M-like mechanism. Nat Commun 10:2146. https://doi.org/10.1038/s41467-019-09981-6

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cassim A, Dun MD, Gallego-Ortega D, Valdes-Mora F (2024) EZHIP’s role in diffuse midline glioma: echoes of oncohistones? Trends Cancer. 2405–8033. https://doi.org/10.1016/j.trecan.2024.09.002. 24)00191-2

Hübner J-M, Müller T, Papageorgiou DN, Mauermann M, Krijgsveld J, Russell RB, Ellison DW, Pfister SM, Pajtler KW, Kool M (2019) EZHIP/CXorf67 mimics K27M mutated oncohistones and functions as an intrinsic inhibitor of PRC2 function in aggressive posterior fossa ependymoma. Neuro Oncol 21:878–889. https://doi.org/10.1093/neuonc/noz058

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jain SU, Rashoff AQ, Krabbenhoft SD, Hoelper D, Do TJ, Gibson TJ, Lundgren SM, Bondra ER, Deshmukh S, Harutyunyan AS et al (2020) H3 K27M and EZHIP impede H3K27-Methylation spreading by inhibiting allosterically stimulated PRC2. Mol Cell. 80:726–735e7. https://doi.org/10.1016/j.molcel.2020.09.028

Article  CAS  PubMed  PubMed Central  Google Scholar 

Han J, Yu M, Bai Y, Yu J, Jin F, Li C, Zeng R, Peng J, Li A, Song X et al (2020) Elevated CXorf67 expression in PFA ependymomas suppresses DNA repair and sensitizes to PARP inhibitors. Cancer Cell 38:844–856e7. https://doi.org/10.1016/j.ccell.2020.10.009

Article  CAS  PubMed  PubMed Central  Google Scholar 

Robertson D, Goldberg MR, Tung CS, Hollister AS, Robertson RM (1986) Use of alpha 2 adrenoreceptor agonists and antagonists in the functional assessment of the sympathetic nervous system. J Clin Invest 78:576–581. https://doi.org/10.1172/JCI112611

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zapotocky M, Beera K, Adamski J, Laperierre N, Guger S, Janzen L, Lassaletta A, Figueiredo Nobre L, Bartels U, Tabori U et al (2019) Survival and functional outcomes of molecularly defined childhood posterior fossa ependymoma: cure at a cost. Cancer 125:1867–1876. https://doi.org/10.1002/cncr.31995

Article  CAS  PubMed  Google Scholar 

Jenseit A, Camgöz A, Pfister SM, Kool M (2022) EZHIP: a new piece of the puzzle towards Understanding pediatric posterior fossa ependymoma. Acta Neuropathol 143:1–13. https://doi.org/10.1007/s00401-021-02382-4

Article  CAS  PubMed  Google Scholar 

Johnston MJ, Lee JJY, Hu B, Nikolic A, Hasheminasabgorji E, Baguette A, Paik S, Chen H, Kumar S, Chen CCL et al (2024) TULIPs decorate the three-dimensional genome of PFA ependymoma. Cell S0092867424006974. https://doi.org/10.1016/j.cell.2024.06.023

Mack SC, Witt H, Piro RM, Gu L, Zuyderduyn S, Stütz AM, Wang X, Gallo M, Garzia L, Zayne K et al (2014) Epigenomic alterations define lethal CIMP-positive ependymomas of infancy. Nature 506:445–450. https://doi.org/10.1038/nature13108

Article  CAS  PubMed  PubMed Central  Google Scholar 

Michealraj KA, Kumar SA, Kim LJY, Cavalli FMG, Przelicki D, Wojcik JB, Delaidelli A, Bajic A, Saulnier O, MacLeod G et al (2020) Metabolic regulation of the epigenome drives lethal infantile ependymoma. Cell 181:1329–1345e24. https://doi.org/10.1016/j.cell.2020.04.047

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pajtler KW, Wen J, Sill M, Lin T, Orisme W, Tang B, Hübner J-M, Ramaswamy V, Jia S, Dalton JD et al (2018) Molecular heterogeneity and CXorf67 alterations in posterior fossa group A (PFA) ependymomas. Acta Neuropathol 136:211–226. https://doi.org/10.1007/s00401-018-1877-0

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dewaele B, Przybyl J, Quattrone A, Finalet Ferreiro J, Vanspauwen V, Geerdens E, Gianfelici V, Kalender Z, Wozniak A, Moerman P et al (2014) Identification of a novel, recurrent MBTD1-CXorf67 fusion in low-grade endometrial stromal sarcoma. Int J Cancer 134:1112–1122. https://doi.org/10.1002/ijc.28440

Article  CAS  PubMed  Google Scholar 

Liu J, Sun D, Lin F, Li Y, Wu T, Liu X (2023) An EWSR1-EZHIP fusion in a cerebral hemisphere astroblastoma. Neuropathology 43:340–344. https://doi.org/10.1111/neup.12893

Article  CAS  PubMed  Google Scholar 

Ryall S, Guzman M, Elbabaa SK, Luu B, Mack SC, Zapotocky M, Taylor MD, Hawkins C, Ramaswamy V (2017) H3 K27M mutations are extremely rare in posterior fossa group A ependymoma. Child’s Nerv Syst 33:1047–1051. https://doi.org/10.1007/s00381-017-3481-3

Article  Google Scholar 

Schwartzentruber J, Korshunov A, Liu XY, Jones DTW, Pfaff E, Jacob K, Sturm D, Fontebasso AM, Quang DAK, Tönjes M et al (2012) Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 482:226–231. https://doi.org/10.1038/nature10833

Article  CAS  PubMed  Google Scholar 

Sturm D, Witt H, Hovestadt V, Khuong-Quang DA, Jones DTW, Konermann C, Pfaff E, Tönjes M, Sill M, Bender S et al (2012) Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell 22:425–437. https://doi.org/10.1016/j.ccr.2012.08.024

Article  CAS  PubMed  Google Scholar 

Khuong-Quang DA, Buczkowicz P, Rakopoulos P, Liu XY, Fontebasso AM, Bouffet E, Bartels U, Albrecht S, Schwartzentruber J, Letourneau L et al (2012) K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic Pontine gliomas. Acta Neuropathol 124:439–447. https://doi.org/10.1007/s00401-012-0998-0

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gröbner SN, Worst BC, Weischenfeldt J, Buchhalter I, Kleinheinz K, Rudneva VA, Johann PD, Balasubramanian GP, Segura-Wang M, Brabetz S et al (2018) The landscape of genomic alterations across childhood cancers. Nature 555:321–327. https://doi.org/10.1038/nature25480

Article  CAS  PubMed  Google Scholar 

Castel D, Kergrohen T, Tauziède-Espariat A, Mackay A, Ghermaoui S, Lechapt E, Pfister SM, Kramm CM, Boddaert N, Blauwblomme T et al (2020) Histone H3 wild-type DIPG/DMG overexpressing EZHIP extend the spectrum diffuse midline gliomas with PRC2 Inhibition beyond H3-K27M mutation. Acta Neuropathol 139:1109–1113. https://doi.org/10.1007/s00401-020-02142-w

Article  PubMed  Google Scholar 

Pun M, Pratt D, Nano PR, Joshi PK, Jiang L, Englinger B, Rao A, Cieslik M, Chinnaiyan AM, Aldape K et al (2023) Common molecular features of H3K27M DMGs and PFA ependymomas map to hindbrain developmental pathways. Acta Neuropathol Commun 11:25. https://doi.org/10.1186/s40478-023-01514-z

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shapiro JA, Gaonkar KS, Spielman SJ, Savonen CL, Bethell CJ, Jin R, Rathi KS, Zhu Y, Egolf LE, Farrow BK et al (2023) OpenPBTA: the open pediatric brain tumor atlas. Cell Genom 3:100340. https://doi.org/10.1016/j.xgen.2023.100340

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cheng J, Novati G, Pan J, Bycroft C, Žemgulytė A, Applebaum T, Pritzel A, Wong LH, Zielinski M, Sargeant T et al (2023) Accurate proteome-wide missense variant effect prediction with alphamissense. Science 381:eadg7492. https://doi.org/10.1126/science.adg7492

Article  CAS  PubMed  Google Scholar 

Varadi M, Bertoni D, Magana P, Paramval U, Pidruchna I, Radhakrishnan M, Tsenkov M, Nair S, Mirdita M, Yeo J et al (2024) AlphaFold protein structure database in 2024: providing structure coverage for over 214 million protein sequences. Nucleic Acids Res 52:D368–D375. https://doi.org/10.1093/nar/gkad1011

Article  CAS  PubMed  Google Scholar 

Jumper J, Evans R, Pritzel A, Green T, Figurnov M, Ronneberger O, Tunyasuvunakool K, Bates R, Žídek A, Potapenko A et al (2021) Highly accurate protein structure prediction with alphafold. Nature 596:583–589. https://doi.org/10.1038/s41586-021-03819-2

Article  CAS  PubMed  PubMed Central